Nivedita Aanur
AbbVie (United States) · 14 works · 711 citations · h-index 9
Top works
- Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
- P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
- Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
- Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
- Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
- Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.
- Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab
- P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153
- CheckMate 77 T: A phase 3 trial of neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) followed by adjuvant NIVO in resectable early-stage non-small cell lung cancer (NSCLC)
- Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC.
- Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.
- Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153.